Skip to main content
. Author manuscript; available in PMC: 2019 Jul 15.
Published in final edited form as: Clin Cancer Res. 2018 Apr 4;24(14):3299–3308. doi: 10.1158/1078-0432.CCR-17-3008

Figure 4. Comparing the overall survival between patients having neither CDKN2A nor interferon gene deletions (purple), patients having CDKN2A deletion only (blue), and patients having both CDKN2A and interferon gene deletions (red).

Figure 4

Survival curves for brain lower grade Glioma (LGG), glioblastoma multiforme (GBM), breast invasive carcinoma (BRCA), lung cancer, colorectal cancer, sarcoma (SARC), ovarian serous cystadenocarcinoma (OV), bladder urothelial carcinoma (BLCA), skin cutaneous melanoma (SKCM) are indicated in panel (A) – (I), respectively. Colorectal cancer is the combined cohort of colon adenocarcinoma (COAD) and rectum adenocarcinoma (READ). Lung cancer is the combined cohort of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). To increase sample size, patients with single copy loss of CDKN2A, truncated mutations of CDKN2A/IFNs/DEFs were also included. Log rank test P-values were calculated by comparing patients having CDKN2A deletion only (blue) with patients having both CDKN2A and interferon gene deletions (red).